Clinical trial

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-03-01

PhasePHASE1

Study timeline

Study start (unknown)2002-03-01Date precision: month

Registry last updated2015-03-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Ovarian Cancerunresolved

Merkel Cell Carcinomaunresolved

SCLCunresolved

Interventions

BB-10901DRUG

Sponsors & collaborators

ImmunoGen, Inc.lead sponsor

Mapped research locations

HoustonTexas, United States1 San FranciscoCalifornia, United States1 SeattleWashington, United States1 ColumbusOhio, United States1 Oklahoma CityOklahoma, United States1 Las VegasNevada, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00346385 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.